Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Next Previous
Trial Profile

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemigatinib (Primary)
  • Indications Adenocarcinoma; Astrocytoma; Bladder cancer; Cervical cancer; Cholangiocarcinoma; CNS cancer; Endometrial cancer; Glioblastoma; Glioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms FIGHT-207
  • Sponsors Incyte Corporation

Most Recent Events

  • 01 Jun 2024 Results assessing safety and efficacy of Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations published in the Nature Medicine
  • 27 Apr 2023 Status changed from discontinued to active, no longer recruiting.
  • 27 Apr 2023 Results assessing the activity of pemigatinib in the subset of patients with previously treated CNS tumors, presented at the 75th Annual Meeting of the American Academy of Neurology 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top